New research at the University of Alberta may make it easier to diagnose serious diseases that disrupt the body's energy ...

BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...

Guggenheim Securities adjusted its price target for Immunovant shares, listed on (NASDAQ:IMVT), to $44.00, a decrease from the previous $46.00, while sustaining a Buy rating on the stock. Currently ...

H.C. Wainwright reaffirmed their Buy rating on Immunovant (NASDAQ:IMVT) shares with a price target of $51.00, aligning with the broader Wall Street sentiment. According to InvestingPro data, analyst ...

Colt Ford’s comeback from his heart attack following a show last April in Arizona has been nothing short of remarkable. The ...

Country star Colt Ford shared that he and Jelly Roll were able to bond over what it’s like to be the “big guys.” ...

Colt Ford’s health journey took a serious turn in 2022 when he was diagnosed with myasthenia gravis, an autoimmune disease ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

"Slow Ride" singer Colt Ford described how he switched to a healthier lifestyle after he "died twice" from a near-fatal heart ...